top of page
Browse by category
Search
Study to analyse the real-world effectiveness of GLP-1 weight-loss drugs and inequities in access to these medications
The Robert Wood Johnson Foundation has awarded a grant to Andrew Stokes, associate professor of global health, Boston University School...
Dose-dependent link between the use of semaglutide and liraglutide injectables and body contouring procedures
There is a dose-dependent link between the use of injectable glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide and...
No association between suicidal, self-injurious thoughts and actions and GLP-1s
The available evidence does not support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) – dulaglutide,...
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
GLP-1RAs may lead to increased risk of aspiration pneumonia following endoscopy
People who are scheduled for certain medical procedures should stop taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)...
Medications for type 2 diabetes and weight loss poorly prescribed
Three independent, preliminary research studies have found that new type 2 diabetes and weight-loss medications are often not prescribed...
GLP-1s do not increase aspiration or pneumonia in surgery patients
There is no association between prescription glucagon-like peptide-1 (GLP-1) agonist medications and increased risk of aspiration or...
GLP1 agonists associated with a reduced risk of developing cirrhosis and liver cancer in people with T2DM and chronic liver disease
Glucagon-like peptide-1 receptor (GLP1) agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people...
Mazdutide demonstrates significant weight loss efficacy and multiple metabolic benefits
The 48-week outcomes from a Phase 2 clinical study of higher dose (9mg) mazdutide in Chinese subjects with obesity have demonstrated...
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...
Browse by tag
bottom of page